Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CD8+ TiLs and T-cell exhaustion

<< Previous

Bullboard Posts

Next >>

Comment by CMHarring218431on May 31, 2024 6:52pm

114 Views

Post# 36067108

RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion

Respect your , in what seems incredible understanding of all biological processes which relate to the incredibly complex cancer stuff. Yes, I said stuff, because it is fascinating and confusing and I'm sure most here say.... what does that mean. Your files and library are apparently at a fingers touch and is beyond any organizational attempt I might try. My point..... to this extreme and complete knowledge of everything Pela.... That has all the time in the world to expound on his knowledge tells me something

<< Previous

Bullboard Posts

Next >>

How to navigate the ups and downs of investing in AI